Fig. 1: Organoid-based small molecule screening with an epigenetic drug library for endometrial cancer.

a Schematic of the high-throughput epigenetic drug Screening. Endometrial cancer cells derived from a primary orthotopic mouse model were cultured with matrigel in 96-well plates. After 24 h of culture, organoids were treated with compounds from an epigenetic drug library of 276 compounds individually. After 72 h of treatment, imaging assay was used to determine organoid number and size. And then, cell viability was analyzed by CCK8 assay. b Left, bright-field image of endometrial cancer organoids, showing morphological characteristics. Scale bar, 50 μm. Right, Haematoxylin and Eosin (H&E) staining of endometrial cancer organoids. Scale bar, 10 μm. c Summary of drug classification in the epigenetic drug library. d Representative images of tumor organoids with the proportions of cell viability at 0%, 50%, and 100%, relative to that of the vehicle treated ones. e The numbers of drugs with which the survival ratios were 0%, 0–10%, 10–50%, 50–100% and more than 100%, relative to the vehicle group. f Incidence of cell viability at 0%, 0–10%, 10–50%, 50–100% and more than 100% after treatment in each kind of target. The numbers above the bars indicated the drug numbers in this class. g Summary of the drug library screening showing the relative survival ratios of tumor organoids treated with individual drug.